3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Terminated
1
Approved for marketing
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Conditions
Nystagmus, Pathologic
1
Myasthenic Syndromes, Congenital
1
Lambert-Eaton Myasthenic Syndrome
1
Interventions
Afatinib
3
niraparib
2
lenvatinib
2
ibrutinib
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Ramucirumab
2
Gefitinib
2
Capecitabine
2
Abiraterone Acetate
2
3-Iodobenzylguanidine
2
zenocutuzumab
1
vorasidenib
1
tucatinib
1
trilaciclib
1
trifluridine tipiracil drug combination
1
tovorafenib
1
talquetamab
1
tafasitamab
1
selpercatinib
1
sacituzumab govitecan
1
ripretinib
1
pralsetinib
1
ponatinib
1
pomalidomide
1
pirtobrutinib
1
pertuzumab
1
olaratumab
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
INDUSTRY
×
Amifampridine
×
Clear all
NCT02189720
2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing